HK1250658A1 - 用於治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化 - Google Patents

用於治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化 Download PDF

Info

Publication number
HK1250658A1
HK1250658A1 HK18110221.0A HK18110221A HK1250658A1 HK 1250658 A1 HK1250658 A1 HK 1250658A1 HK 18110221 A HK18110221 A HK 18110221A HK 1250658 A1 HK1250658 A1 HK 1250658A1
Authority
HK
Hong Kong
Prior art keywords
group
trpc6
compound
alzheimer
disease
Prior art date
Application number
HK18110221.0A
Other languages
English (en)
Chinese (zh)
Inventor
伊利亚‧贝兹普罗兹万内
伊利亞‧貝茲普羅茲萬內
张华�
張華
Original Assignee
得克萨斯州大学系统董事会
得克薩斯州大學系統董事會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 得克萨斯州大学系统董事会, 得克薩斯州大學系統董事會 filed Critical 得克萨斯州大学系统董事会
Publication of HK1250658A1 publication Critical patent/HK1250658A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18110221.0A 2015-05-08 2016-05-04 用於治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化 HK1250658A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562159083P 2015-05-08 2015-05-08
US62/159,083 2015-05-08
PCT/US2016/030704 WO2016182812A1 (en) 2015-05-08 2016-05-04 Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
HK1250658A1 true HK1250658A1 (zh) 2019-01-11

Family

ID=57248333

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110221.0A HK1250658A1 (zh) 2015-05-08 2016-05-04 用於治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化

Country Status (6)

Country Link
US (1) US20180147206A1 (enExample)
JP (1) JP2018515507A (enExample)
KR (1) KR20180004242A (enExample)
CN (1) CN107835688A (enExample)
HK (1) HK1250658A1 (enExample)
WO (1) WO2016182812A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759985B (zh) * 2018-07-27 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种用于微波辐射致神经元钙信号调节的生物标志物Orai2蛋白
RU2676100C1 (ru) * 2018-10-05 2018-12-26 федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский политехнический университет Петра Великого" (ФГАОУ ВО "СПбПУ") Применение производных пиперазина для лечения болезни Альцгеймера и деменций альцгеймеровского типа с нарушенной внутриклеточной кальциевой сигнализацией
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
US8598344B2 (en) * 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
US9393244B2 (en) * 2013-03-15 2016-07-19 Georgetown University Increasing parkin activity by administering a deubiquitinating enzyme inhibitor

Also Published As

Publication number Publication date
JP2018515507A (ja) 2018-06-14
WO2016182812A8 (en) 2017-03-09
CN107835688A (zh) 2018-03-23
US20180147206A1 (en) 2018-05-31
KR20180004242A (ko) 2018-01-10
WO2016182812A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
El Gaamouch et al. VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice
Zhu et al. Beta-site amyloid precursor protein cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure protein 6
Zhang et al. Store-operated calcium channel complex in postsynaptic spines: a new therapeutic target for Alzheimer's disease treatment
Wang et al. The essential role of soluble Aβ oligomers in Alzheimer’s disease
Xia et al. C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer’s disease
Liu et al. Orexin-A exerts neuroprotective effects via OX1R in Parkinson’s disease
Avetisyan et al. Mitochondrial dysfunction in neocortex and hippocampus of olfactory bulbectomized mice, a model of Alzheimer’s disease
Trinh et al. Adenosine receptor signalling in Alzheimer’s disease
Trazzi et al. APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome
RS52941B (sr) Kombinacija alfa 7 nikotinskih agonista i antipsihotika
Vargas et al. WASP-1, a canonical Wnt signaling potentiator, rescues hippocampal synaptic impairments induced by Aβ oligomers
Liu et al. Plasmalogen attenuates the development of hepatic steatosis and cognitive deficit through mechanism involving p75NTR inhibition
JP6267160B2 (ja) アルツハイマー病等を含む神経疾患の１，２５ｄ３−ｍａｒｒｓが関与する治療薬及び治療法
JP2018076332A (ja) （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
Yang et al. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer’s disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction
Takeuchi et al. Alleviation of Aβ-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model
Riku Reappraisal of the anatomical spreading and propagation hypothesis about TDP‐43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
Li et al. Ube2c-inhibition alleviated amyloid pathology and memory deficits in APP/PS1 mice model of AD
HK1250658A1 (zh) 用於治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化
Kelliny et al. Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches
AU2019350443A1 (en) Combination of acetylcholinesterase inhibitor and 5-HT4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
KR102393125B1 (ko) 켐페라이드를 유효성분으로 포함하고 오토파지 유도 활성을 갖는 단백질 형태이상 질환의 예방 또는 치료용 조성물
Tian et al. GALM Alleviates Aβ Pathology and Cognitive Deficit Through Increasing ADAM10 Maturation in a Mouse Model of Alzheimer’s Disease
CN110623960B (zh) 一种小分子化合物在制备治疗阿尔茨海默病的药物中的应用
Allain et al. Experimental and clinical methods in the development of anti‐Alzheimer drugs